Erin Cvejic

Dr. Erin Cvejic

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
Rachael DoddRachael Dodd
Rachael Dodd
ECErin Cvejic
Erin Cvejic
CBCarissa Bonner
Carissa Bonner
KPKristen Pickles
Kristen Pickles
KMKirsten J McCaffery
Kirsten J McCaffery
Brooke NickelBrooke Nickel
Brooke Nickel

10 December 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JIJennifer Mj Isautier
Jennifer Mj Isautier
Tessa CoppTessa Copp
Tessa Copp
JAJulie Ayre
Julie Ayre
ECErin Cvejic
Erin Cvejic
GMGideon Meyerowitz-Katz
Gideon Meyerowitz-Katz
KMKirsten J McCaffery
Kirsten J McCaffery
Background: In response to the COVID-19 pandemic, telehealth has rapidly been adopted to deliver health care services around the world. To date, studies have not compared people’s experiences with telehealth services during the pandemic in Australia to their experiences with traditional in-person visits. Objective: This study aimed to compare participants’ perceptions of telehealth consults to their perceptions of traditional in-person visits and investigate whether people believe that telehealth services would be useful after the pandemic. Methods: A national, cross-sectional, community survey was conducted between June 5 and June 12, 2020 in Australia. In total, 1369 participants who were aged ≥18 years and lived in Australia were recruited via targeted advertisements on social media (ie, Facebook and Instagram). Participants responded to survey questions about their telehealth experience, which included a free-text response option. A generalized linear model was used to estimate the adjusted relative risks of having a poorer telehealth experience than a traditional in-person visit experience. Content analysis was performed to determine the reasons why telehealth experiences were worse than traditional in-person visit experiences. Results: Of the 596 telehealth users, the majority of respondents (n=369, 61.9%) stated that their telehealth experience was “just as good as” or “better than” their traditional in-person medical appointment experience. On average, respondents perceived that telehealth would be moderately useful to very useful for medical appointments after the COVID-19 pandemic ends (mean 3.67, SD 1.1). Being male (P=.007), having a history of both depression and anxiety (P=.016), and lower patient activation scores (ie, individuals’ willingness to take on the role of managing their health/health care) (P=.036) were significantly associated with a poor telehealth experience. In total, 6 overarching themes were identified from free-text responses for why participants’ telehealth experiences were poorer than their traditional in-person medical appointment experiences, as follows: communication is not as effective, limitations with technology, issues with obtaining prescriptions and pathology results, reduced confidence in their doctor, additional burden for complex care, and inability to be physically examined. Conclusions: Based on our sample’s responses, telehealth appointment experiences were comparable to traditional in-person medical appointment experiences. Telehealth may be worthwhile as a mode of health care delivery while the pandemic continues, and it may continue to be worthwhile after the pandemic.

7 January 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
KPKristen Pickles
Kristen Pickles
ECErin Cvejic
Erin Cvejic
Brooke NickelBrooke Nickel
Brooke Nickel
Tessa CoppTessa Copp
Tessa Copp
CBCarissa Bonner
Carissa Bonner
KMKirsten J McCaffery
Kirsten J McCaffery
Background: Misinformation about COVID-19 is common and has been spreading rapidly across the globe through social media platforms and other information systems. Understanding what the public knows about COVID-19 and identifying beliefs based on misinformation can help shape effective public health communications to ensure efforts to reduce viral transmission are not undermined. Objective: This study aimed to investigate the prevalence and factors associated with COVID-19 misinformation in Australia and their changes over time. Methods: This prospective, longitudinal national survey was completed by adults (18 years and above) across April (n=4362), May (n=1882), and June (n=1369) 2020. Results: Stronger agreement with misinformation was associated with younger age, male gender, lower education level, and language other than English spoken at home (P<.01 for all). After controlling for these variables, misinformation beliefs were significantly associated (P<.001) with lower levels of digital health literacy, perceived threat of COVID-19, confidence in government, and trust in scientific institutions. Analyses of specific government-identified misinformation revealed 3 clusters: prevention (associated with male gender and younger age), causation (associated with lower education level and greater social disadvantage), and cure (associated with younger age). Lower institutional trust and greater rejection of official government accounts were associated with stronger agreement with COVID-19 misinformation. Conclusions: The findings of this study highlight important gaps in communication effectiveness, which must be addressed to ensure effective COVID-19 prevention.

1 October 2017 in International Journal of Psychophysiology
Verified
Journal Article
Closed access
ELEmily Lynar
Emily Lynar
ECErin Cvejic
Erin Cvejic
ESEmery Schubert
Emery Schubert
UVUte Vollmer-Conna
Ute Vollmer-Conna

23 August 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
HVHelen Vidot
Helen Vidot
ECErin Cvejic
Erin Cvejic
SCSharon Carey
Sharon Carey
SSSimone Irene Strasser
Simone Irene Strasser
GMGeoff McCaughan
Geoff McCaughan
NSNicholas Adam Shackel
Nicholas Adam Shackel
Summary: Background: Painful muscle cramps occur in the majority of patients with cirrhosis impacting significantly on quality of life and sleep patterns. They are frequently unrecognised or overlooked. Current management is based on anecdotal evidence or case study reports.Aim: To investigate the effect of oral taurine supplementation on frequency, duration, and intensity of muscle cramps in patients with chronic liver disease.Methods: Patients with chronic liver disease who experienced three or more muscle cramps/week were enrolled in a double‐blinded, randomised control, crossover, taurine dose‐variable study. Each participant received either taurine supplementation or placebo for 4 weeks then crossed to the alternative arm. Primary outcome data for frequency, duration, and intensity of muscle cramps was recorded by participants. Participants recorded frequency, duration, and location of muscle cramps. Biochemical parameters, including serum taurine and methionine levels, were measured at each time point. Linear mixed models were used to analyse outcomes.Results: Forty‐nine patients were enrolled in the study and 30 patients completed the protocol. Participants who were unable to complete the protocol were not included in the final analysis due to the absence of outcome data. The mean age of participants was 54.7 years and 70% were males. Oral taurine supplementation increased serum taurine levels (P < 0.001). There were no adverse side effects associated with taurine supplementation. Participants receiving 2 g taurine/d experienced a reduction in cramp frequency (seven cramps fewer/fortnight, P = 0.03), duration (89 minutes less/fortnight P = 0.03), and severity (1.4 units less on a Likert scale P < 0.004) compared to placebo.Conclusions: Oral supplementation with 2 g taurine/d results in a clinically significant reduction in the frequency, duration, and intensity of muscle cramps in patients with chronic liver disease. Taurine should be considered as a safe and effective intervention in the management of muscle cramps in individuals with chronic liver disease.This study was registered with the Australian New Zealand Clinical Trials Register: ACTRN12612000289819.

1 January 2019 in International Journal of Cardiology
Verified
Journal Article
Closed access
JTJason Por How Tan
Jason Por How Tan
JBJessica Elise Beilharz
Jessica Elise Beilharz
UVUté Vollmer-Conna
Uté Vollmer-Conna
ECErin Cvejic
Erin Cvejic